EGFR野生型（wt）進行非小細胞肺癌（NSCLC）患者における経口cMET阻害剤INC280の研究（ジオメトリーモノ-1）

基本情報

NCT ID

NCT02414139

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

373

治験依頼者名

Novartis

概要

Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.

対象疾患

介入

依頼者（Sponsor）